When was Quartz Bio founded?

Quartz Bio was founded in 2012 and raised its 1st funding round 14 years after it was founded.

Where is Quartz Bio located?

Quartz Bio is headquartered in Geneva, Switzerland.

How many employees does Quartz Bio have?

As of Jun 30, 2026, the latest employee count at Quartz Bio is 62.

Is Quartz Bio a funded company?

Quartz Bio is a funded company, having raised a total of $***** in its 1st and only funding round, a PE round on May 13, 2026.

When was the latest funding round of Quartz Bio?

Quartz Bio's latest funding was a $***** PE round on May 13, 2026, with participation from 1 investor.

Where does Quartz Bio rank among its competitors?

Quartz Bio ranks 233rd amongst 1957 active competitors, of which 452 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Quartz Bio, which secured an undisclosed amount in May, 2026.

Who are the top competitors of Quartz Bio?

Quartz Bio's top competitors include Synthego, Antheia and Transcenta. Among them, Quartz Bio secured the most recent funding round in May, 2026.

Quartz Bio - 2026 Company Profile, Team, Funding & Competitors

Company Details

Quartz Bio is a clinical bioinformatics and biostatistics services company that analyzes biomarker data from clinical trials for its clients, which include pharmaceutical and diagnostics companies. The company's service pipeline starts from the design of experiment to development of statistical analysis plan, followed by the analysis and patient stratification, visualizations and a detailed reporting. The company claims that its strength lies in exploratory data analysis, and in the design of experiments, generation of manual of operations for large exploratory studies to ensure proper data collection.

Website: www.quartz.bio/
Social
Email ID: *****@quartz.bio

Key Metrics

Founded Year

2012

Location

Geneva, Switzerland

Stage

Acquired

Latest Funding Round

PE, May 13, 2026, $*****

Investors

Eir Partners & 1 more

Ranked

233^rd among 1957 active competitors

Employee Count

62 as on Jun 30, 2026

Investment & Acquisitions

SolveBio

Similar Companies

Synthego & 2666 more

Exit Details

Acquired by Precision Medicine Group (Jan 10, 2018)

View Quartz Bio's full profile

Quartz Bio got acquired by Precision Medicine Group on Jan 10, 2018.

Click here to take a look at Quartz Bio's acquisition in detail

Quartz Bio has raised funding over 1 round. Its latest funding round was a PE round on May 13, 2026 for $*****. 1 investor participated in its latest round. Quartz Bio has 2 institutional investors.

Here is the list of recent funding rounds of Quartz Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 13, 2026	8942666	PE	3684583	8381315	8357255	9018337

Access funding benchmarks and valuations. Sign up today!

View details of Quartz Bio's funding rounds and investors

The founders of Quartz Bio are Karl Forner, Jerome Wojcik and Alessandro Di Cara.

Here are the details of Quartz Bio's key team members:

Karl Forner: Co-Founder of Quartz Bio.
Jerome Wojcik: Founder & CEO of Quartz Bio.
Alessandro Di Cara: Co-Founder of Quartz Bio.

View details of Quartz Bio's Founder profiles and Board Members

Quartz Bio's employee count trend

Quartz Bio has 62 employees as of Jun 26. Here is Quartz Bio's employee count trend over the years:

Uncover Quartz Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Quartz Bio include Synthego, Antheia and Transcenta. Here is the list of Top 10 competitors of Quartz Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, Perceptive Advisors & 30 others	71/100
2nd	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
3rd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
4th	Judges Scientific 2002, London (United Kingdom), Public	Acquisition and development of scientific instrument businesses	-	Origin Capital, Lloyds Banking Group	65/100
5th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Orbimed, Sino Biopharmaceutical & 18 others	65/100
6th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Fidelity Investments ... & 14 others	64/100
7th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Bpifrance & 14 others	63/100
8th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	UBS, Brown Brothers Harriman & 1 others	63/100
9th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$346M	Maverick Ventures, Polaris Partners & 16 others	62/100
10th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	62/100
233rd	Quartz Bio 2012, Geneva (Switzerland), Acquired	Bioinformatics services for biomarker analysis	-	Eir Partners, Fongit	42/100